DAG1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: As a result, this enhanced laminin binding to dystroglycan, suggesting the potential for ribitol to enhance muscle function in dystroglycanopathy patients with an FKRP mutation.